BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 954 filers reported holding BAXTER INTL INC in Q1 2014. The put-call ratio across all filers is 0.58 and the average weighting 0.5%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $354,000 | +6.9% | 4,803 | -5.8% | 0.06% | +9.8% |
| Q1 2018 | $331,000 | +0.3% | 5,100 | 0.0% | 0.05% | +2.0% |
| Q4 2017 | $330,000 | +4.1% | 5,100 | +1.0% | 0.05% | +4.2% |
| Q3 2017 | $317,000 | +3.6% | 5,050 | +0.0% | 0.05% | +2.1% |
| Q2 2017 | $306,000 | +2.7% | 5,049 | -12.1% | 0.05% | 0.0% |
| Q1 2017 | $298,000 | +18.3% | 5,743 | +1.1% | 0.05% | +23.7% |
| Q4 2016 | $252,000 | -7.0% | 5,680 | 0.0% | 0.04% | -9.5% |
| Q3 2016 | $271,000 | -63.9% | 5,680 | -65.8% | 0.04% | -25.0% |
| Q2 2016 | $750,000 | +22.1% | 16,585 | +10.9% | 0.06% | +14.3% |
| Q1 2016 | $614,000 | -39.9% | 14,950 | -44.2% | 0.05% | -43.0% |
| Q4 2015 | $1,021,000 | +140.8% | 26,776 | +107.1% | 0.09% | +145.7% |
| Q3 2015 | $424,000 | -72.6% | 12,931 | -41.6% | 0.04% | -84.9% |
| Q2 2015 | $1,549,000 | -12.3% | 22,151 | -14.1% | 0.23% | -9.7% |
| Q1 2015 | $1,766,000 | +172.1% | 25,786 | +191.1% | 0.26% | +185.6% |
| Q4 2014 | $649,000 | +10.4% | 8,858 | +8.1% | 0.09% | +11.1% |
| Q3 2014 | $588,000 | +19.0% | 8,193 | +20.1% | 0.08% | +20.9% |
| Q2 2014 | $494,000 | +24.1% | 6,823 | +26.4% | 0.07% | +36.7% |
| Q1 2014 | $398,000 | – | 5,398 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |